Targeting the PI3K/Akt pathway in prostate cancer: Challenges and opportunities (Review)
- Authors:
- Paul Toren
- Amina Zoubeidi
-
Affiliations: The Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia V6H 3Z6, Canada - Published online on: August 14, 2014 https://doi.org/10.3892/ijo.2014.2601
- Pages: 1793-1801
This article is mentioned in:
Abstract
 |
 |
|
What are the key statistics about prostate cancer? American Cancer Society. http://www.cancer.org/cancer/prostatecancer/detailedguide/prostate-cancer-key-statistics. Accessed April 27, 2014 | |
|
Scher HI, Fizazi K, Saad F, et al: Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 367:1187–1197. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Ryan CJ, Smith MR, de Bono JS, et al: Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 368:138–148. 2013. View Article : Google Scholar | |
|
Donahue TR, Tran LM, Hill R, et al: Integrative survival-based molecular profiling of human pancreatic cancer. Clin Cancer Res. 18:1352–1363. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Martini M, Ciraolo E, Gulluni F and Hirsch E: Targeting PI3K in cancer: any good news? Front Oncol. 3:1082013. View Article : Google Scholar | |
|
Jia S, Liu Z, Zhang S, et al: Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis. Nature. 454:776–779. 2008.PubMed/NCBI | |
|
Jiang X, Chen S, Asara JM and Balk SP: Phosphoinositide 3-kinase pathway activation in phosphate and tensin homolog (PTEN)-deficient prostate cancer cells is independent of receptor tyrosine kinases and mediated by the p110beta and p110delta catalytic subunits. J Biol Chem. 285:14980–14989. 2010. View Article : Google Scholar | |
|
Drake JM, Graham NA, Lee JK, et al: Metastatic castration-resistant prostate cancer reveals intrapatient similarity and interpatient heterogeneity of therapeutic kinase targets. Proc Natl Acad Sci USA. 110:E4762–E4769. 2013. View Article : Google Scholar | |
|
Kremer CL, Klein RR, Mendelson J, et al: Expression of mTOR signaling pathway markers in prostate cancer progression. Prostate. 66:1203–1212. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Bitting RL and Armstrong AJ: Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer. Endocr Relat Cancer. 20:R83–R99. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Dibble CC, Asara JM and Manning BD: Characterization of Rictor phosphorylation sites reveals direct regulation of mTOR complex 2 by S6K1. Mol Cell Biol. 29:5657–5670. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Cantley LC: The phosphoinositide 3-kinase pathway. Science. 296:1655–1657. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Ellis L, Ku SY, Ramakrishnan S, et al: Combinatorial antitumor effect of HDAC and the PI3K-Akt-mTOR pathway inhibition in a Pten defecient model of prostate cancer. Oncotarget. 4:2225–2236. 2013.PubMed/NCBI | |
|
Yue S, Li J, Lee SY, et al: Cholesteryl ester accumulation induced by PTEN loss and PI3K/AKT activation underlies human prostate cancer aggressiveness. Cell Metab. 19:393–406. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Muniyan S, Ingersoll MA, Batra SK and Lin MF: Cellular prostatic acid phosphatase, a PTEN-functional homologue in prostate epithelia, functions as a prostate-specific tumor suppressor. Biochim Biophys Acta. pii: S0304-419X(14)00042-0. Apr 18–2014.(Epub ahead of print). View Article : Google Scholar | |
|
Hodgson MC, Shao LJ, Frolov A, et al: Decreased expression and androgen regulation of the tumor suppressor gene INPP4B in prostate cancer. Cancer Res. 71:572–582. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Carver BS, Chapinski C, Wongvipat J, et al: Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell. 19:575–586. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Phin S, Moore MW and Cotter PD: Genomic rearrangements of in prostate cancer. Front Oncol. 3:2402013. View Article : Google Scholar | |
|
Fata JE, Debnath S, Jenkins EC Jr and Fournier MV: Nongenomic mechanisms of PTEN regulation. Int J Cell Biol. 2012:3796852012.PubMed/NCBI | |
|
Ahmad I, Patel R, Singh LB, et al: HER2 overcomes PTEN (loss)-induced senescence to cause aggressive prostate cancer. Proc Natl Acad Sci USA. 108:16392–16397. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Zu K, Martin NE, Fiorentino M, et al: Protein expression of PTEN, insulin-like growth factor I receptor (IGF-IR), and lethal prostate cancer: a prospective study. Cancer Epidemiol Biomarkers Prev. 22:1984–1993. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Nacerddine K, Beaudry JB, Ginjala V, et al: Akt-mediated phosphorylation of Bmi1 modulates its oncogenic potential, E3 ligase activity, and DNA damage repair activity in mouse prostate cancer. J Clin Invest. 122:1920–1932. 2012. View Article : Google Scholar | |
|
Dubrovska A, Kim S, Salamone RJ, et al: The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations. Proc Natl Acad Sci USA. 106:268–273. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Wang S, Gao J, Lei Q, et al: Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell. 4:209–221. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Blando J, Portis M, Benavides F, et al: PTEN deficiency is fully penetrant for prostate adenocarcinoma in C57BL/6 mice via mTOR-dependent growth. Am J Pathol. 174:1869–1879. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Mulholland DJ, Tran LM, Li Y, et al: Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth. Cancer Cell. 19:792–804. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Xin L, Teitell MA, Lawson DA, Kwon A, Mellinghoff IK and Witte ON: Progression of prostate cancer by synergy of AKT with genotropic and nongenotropic actions of the androgen receptor. Proc Natl Acad Sci USA. 103:7789–7794. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Baca Sylvan C, Prandi D, Lawrence Michael S, et al: Punctuated evolution of prostate cancer genomes. Cell. 153:666–677. 2013.PubMed/NCBI | |
|
Nguyen AH, Tremblay M, Haigh K, et al: Gata3 antagonizes cancer progression in Pten-deficient prostates. Hum Mol Genet. 22:2400–2410. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Ai J, Pascal LE, O’Malley KJ, et al: Concomitant loss of EAF2/U19 and Pten synergistically promotes prostate carcinogenesis in the mouse model. Oncogene. 33:2286–2294. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Thomsen MK, Ambroisine L, Wynn S, et al: SOX9 elevation in the prostate promotes proliferation and cooperates with PTEN loss to drive tumor formation. Cancer Res. 70:979–987. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Kim MJ, Cardiff RD, Desai N, et al: Cooperativity of Nkx3.1 and Pten loss of function in a mouse model of prostate carcinogenesis. Proc Natl Acad Sci USA. 99:2884–2889. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Song H, Zhang B, Watson MA, Humphrey PA, Lim H and Milbrandt J: Loss of Nkx3.1 leads to the activation of discrete downstream target genes during prostate tumorigenesis. Oncogene. 28:3307–3319. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Chen Z, Trotman LC, Shaffer D, et al: Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature. 436:725–730. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Blando JM, Carbajal S, Abel E, et al: Cooperation between Stat3 and Akt signaling leads to prostate tumor development in transgenic mice. Neoplasia. 13:254–265. 2011.PubMed/NCBI | |
|
Ding Z, Wu CJ, Chu GC, et al: SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression. Nature. 470:269–273. 2011. View Article : Google Scholar | |
|
Wang J, Kobayashi T, Floc’h N, et al: B-Raf activation cooperates with PTEN loss to drive c-Myc expression in advanced prostate cancer. Cancer Res. 72:4765–4776. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Thomas C, Lamoureux F, Crafter C, et al: Synergistic targeting of PI3K/AKT pathway and androgen receptor axis significantly delays castration-resistant prostate cancer progression in vivo. Mol Cancer Ther. 12:2342–2355. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Wang Y, Kreisberg JI and Ghosh PM: Cross-talk between the androgen receptor and the phosphatidylinositol 3-kinase/Akt pathway in prostate cancer. Curr Cancer Drug Targets. 7:591–604. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Kaarbo M, Mikkelsen OL, Malerod L, et al: PI3K-AKT-mTOR pathway is dominant over androgen receptor signaling in prostate cancer cells. Cell Oncol. 32:11–27. 2010.PubMed/NCBI | |
|
Chandarlapaty S, Sawai A, Scaltriti M, et al: AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell. 19:58–71. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Wen Y, Hu MCT, Makino K, et al: HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway. Cancer Res. 60:6841–6845. 2000.PubMed/NCBI | |
|
Manin M, Baron S, Goossens K, et al: Androgen receptor expression is regulated by the phosphoinositide 3-kinase/Akt pathway in normal and tumoral epithelial cells. Biochem J. 366:729–736. 2002.PubMed/NCBI | |
|
Nan B, Snabboon T, Unni E, X-J Y, Whang Y and Marcelli M: The PTEN tumor suppressor is a negative modulator of androgen receptor transcriptional activity. J Mol Endocrinol. 31:169–183. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Schwartz S, Carver B, Wongvipat J, et al: The antitumor effects of PI3K beta inhibitors in PTEN negative prostate cancer are enhanced by inhibition of reactivated PI3K alpha signaling. In: Proc 105th Annual Meeting Amer Assoc Cancer Res; abs. 4774. 2014 | |
|
Toren P, Kim S, Gleave M and Zoubeidi A: Combined targeting of PI3K/Akt and AR pathway with AZD5363 and enzalutamide induces anticancer activity in preclinical models of prostate cancer. J Urol. 189(Suppl l4): e4032013. View Article : Google Scholar | |
|
Taylor BS, Schultz N, Hieronymus H, et al: Integrative genomic profiling of human prostate cancer. Cancer Cell. 18:11–22. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Attard G, Swennenhuis JF, Olmos D, et al: Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. Cancer Res. 69:2912–2918. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Jendrossek V, Henkel M, Hennenlotter J, et al: Analysis of complex protein kinase B signalling pathways in human prostate cancer samples. BJU Int. 102:371–382. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Jia S, Gao X, Lee SH, et al: Opposing effects of androgen deprivation and targeted therapy on prostate cancer prevention. Cancer Discov. 3:44–51. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Sircar K, Yoshimoto M, Monzon FA, et al: PTEN genomic deletion is associated with p-Akt and AR signalling in poorer outcome, hormone refractory prostate cancer. J Pathol. 218:505–513. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Schmidt H, DeAngelis G, Eltze E, Gockel I, Semjonow A and Brandt B: Asynchronous growth of prostate cancer is reflected by circulating tumor cells delivered from distinct, even small foci, harboring loss of heterozygosity of the PTEN gene. Cancer Res. 66:8959–8965. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Janku F, Tsimberidou AM, Garrido-Laguna I, et al: PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors. Mol Cancer Ther. 10:558–565. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
McMenamin ME, Soung P, Perera S, Kaplan I, Loda M and Sellers WR: Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. Cancer Res. 59:4291–4296. 1999.PubMed/NCBI | |
|
Dreher T, Zentgraf H, Abel U, et al: Reduction of PTEN and p27kip1 expression correlates with tumor grade in prostate cancer. Analysis in radical prostatectomy specimens and needle biopsies. Virchows Arch. 444:509–517. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Schmitz M, Grignard G, Margue C, et al: Complete loss of PTEN expression as a possible early prognostic marker for prostate cancer metastasis. Int J Cancer. 120:1284–1292. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Koumakpayi IH, Le Page C, Mes-Masson AM and Saad F: Hierarchical clustering of immunohistochemical analysis of the activated ErbB/PI3K/Akt/NF-kappaB signalling pathway and prognostic significance in prostate cancer. Br J Cancer. 102:1163–1173. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Malik SN, Brattain M, Ghosh PM, et al: Immunohistochemical demonstration of phospho-Akt in high Gleason grade prostate cancer. Clin Cancer Res. 8:1168–1171. 2002.PubMed/NCBI | |
|
Hammarsten P, Cipriano M, Josefsson A, et al: Phospho-Akt immunoreactivity in prostate cancer: relationship to disease severity and outcome, Ki67 and phosphorylated EGFR expression. PLoS One. 7:e479942012. View Article : Google Scholar : PubMed/NCBI | |
|
McCall P, Gemmell LK, Mukherjee R, Bartlett JM and Edwards J: Phosphorylation of the androgen receptor is associated with reduced survival in hormone-refractory prostate cancer patients. Br J Cancer. 98:1094–1101. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Bedolla R, Prihoda TJ, Kreisberg JI, et al: Determining risk of biochemical recurrence in prostate cancer by immunohistochemical detection of PTEN expression and Akt activation. Clin Cancer Res. 13:3860–3867. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Won JR, Gao D, Chow C, et al: A survey of immunohistochemical biomarkers for basal-like breast cancer against a gene expression profile gold standard. Mod Pathol. 26:1438–1450. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Van de Sande T, Roskams T, Lerut E, et al: High-level expression of fatty acid synthase in human prostate cancer tissues is linked to activation and nuclear localization of Akt/PKB. J Pathol. 206:214–219. 2005.PubMed/NCBI | |
|
Templeton AJ, Dutoit V, Cathomas R, et al: Phase 2 trial of single-agent everolimus in chemotherapy-naive patients with castration-resistant prostate cancer (SAKK 08/08). Eur Urol. 64:150–158. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Wagle N, Grabiner BC, Van Allen EM, et al: Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib. Cancer Discov. 4:546–553. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Banerji U: Results of two phase 1 multicenter trials of AZD5363, an inhibitor of AKT1, 2 and 3: biomarker and early clinical evaluation in Western and Japanese patients with advanced solid tumors. In: 2013, Proc Annual Meeting Amer Assoc Cancer Res (abstract LB-66); 2013; | |
|
Chee KG, Longmate J, Quinn DI, et al: The AKT inhibitor perifosine in biochemically recurrent prostate cancer: a phase II California/Pittsburgh cancer consortium trial. Clin Genitourin Cancer. 5:433–437. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Posadas EM, Gulley J, Arlen PM, et al: A phase II study of perifosine in androgen independent prostate cancer. Cancer Biol Ther. 4:1133–1137. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Bendell JC, Ervin TE, Senzer N, et al: Results of the X-PECT study: a phase III randomized double-blind, placebo-controlled study of perifosine plus capecitabine (P-CAP) versus placebo plus capecitabine (CAP) in patients (pts) with refractory metastatic colorectal cancer (mCRC). J Clin Oncol. 30:LBA35012012. | |
|
Busaidy NL, Farooki A, Dowlati A, et al: Management of metabolic effects associated with anticancer agents targeting the PI3K-Akt-mTOR pathway. J Clin Oncol. 30:2919–2928. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Bendell JC, Rodon J, Burris HA, et al: Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors. J Clin Oncol. 30:282–290. 2012. View Article : Google Scholar | |
|
Amato RJ, Wilding G, Bubley G, Loewy J, Haluska F and Gross ME: Safety and preliminary efficacy analysis of the mTOR inhibitor ridaforolimus in patients with taxane-treated, castration-resistant prostate cancer. Clin Genitourin Cancer. 10:232–238. 2012. View Article : Google Scholar | |
|
Hsieh AC, Liu Y, Edlind MP, et al: The translational landscape of mTOR signalling steers cancer initiation and metastasis. Nature. 485:55–61. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Mateo J, Schoffski P, Olmos D, et al: Abstract B187: Pharmacodynamics of OSI-027, a dual mTORC1/mTORC2 inhibitor, in tumor and surrogate tissues: Results from the expansion phase of a first-in-man study. Mol Cancer Ther. 12:B1872013. View Article : Google Scholar | |
|
Baselga J, Campone M, Piccart M, et al: Everolimus in post-menopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 366:520–529. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Floc’h N, Kinkade CW, Kobayashi T, et al: Dual targeting of the Akt/mTOR signaling pathway inhibits castration-resistant prostate cancer in a genetically engineered mouse model. Cancer Res. 72:4483–4493. 2012.PubMed/NCBI | |
|
Squillace RM, Miller D, Wardwell SD, Wang F, Clackson T and Rivera VM: Synergistic activity of the mTOR inhibitor ridaforolimus and the antiandrogen bicalutamide in prostate cancer models. Int J Oncol. 41:425–432. 2012.PubMed/NCBI | |
|
Nakabayashi M, Werner L, Courtney KD, et al: Phase II trial of RAD001 and bicalutamide for castration-resistant prostate cancer. BJU Int. 110:1729–1735. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Pan C, Robles D, D’Abronzo L, et al: Synergistic effects of everolimus and bicalutamide in castration-resistant prostate cancer: results from a phase I/II clinical trial. Cancer Res. 72:57502012. View Article : Google Scholar | |
|
Patnaik A, Loda M, Kung J, et al: A phase Ib study of BKM120 combined with abiraterone acetate for castrate-resistant, metastatic prostate cancer. In: Proc 105th Annual Meeting Amer Assoc Cancer Res; abs. CT418. 2014 | |
|
Janne PA, Cohen RB, Laird AD, et al: Phase I safety and pharmacokinetic study of the PI3K/mTOR inhibitor SAR245409 (XL765) in combination with erlotinib in patients with advanced solid tumors. J Thorac Oncol. 9:316–323. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Meulenbeld HJ, de Bono JS, Tagawa ST, et al: Tolerability, safety and pharmacokinetics of ridaforolimus in combination with bicalutamide in patients with asymptomatic, metastatic castration-resistant prostate cancer (CRPC). Cancer Chemother Pharmacol. 72:909–916. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Baiz D, Hassan S, Choi YA, et al: Combination of the PI3K inhibitor ZSTK474 with a PSMA-targeted immunotoxin accelerates apoptosis and regression of prostate cancer. Neoplasia. 15:1172–1183. 2013.PubMed/NCBI | |
|
Yasumizu Y, Miyajima A, Kosaka T, Miyazaki Y, Kikuchi E and Oya M: Dual PI3K/mTOR inhibitor NVP-BEZ235 sensitizes docetaxel in castration resistant prostate cancer. J Urol. 191:227–234. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Lamoureux F, Thomas C, Crafter C, et al: Blocked autophagy using lysosomotropic agents sensitizes resistant prostate tumor cells to the novel Akt inhibitor AZD5363. Clin Cancer Res. 19:833–844. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Cen B, Mahajan S, Wang W and Kraft AS: Elevation of receptor tyrosine kinases by small molecule AKT inhibitors in prostate cancer is mediated by Pim-1. Cancer Res. 73:3402–3411. 2013. View Article : Google Scholar | |
|
Kinkade CW, Castillo-Martin M, Puzio-Kuter A, et al: Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model. J Clin Invest. 118:3051–3064. 2008.PubMed/NCBI | |
|
Tai S, Sun Y, Liu N, et al: Combination of Rad001 (everolimus) and propachlor synergistically induces apoptosis through enhanced autophagy in prostate cancer cells. Mol Cancer Ther. 11:1320–1331. 2012. View Article : Google Scholar | |
|
Festuccia C, Gravina GL, Muzi P, et al: Akt down-modulation induces apoptosis of human prostate cancer cells and synergizes with EGFR tyrosine kinase inhibitors. Prostate. 68:965–974. 2008. View Article : Google Scholar : PubMed/NCBI |
